Adient (FRA:18I) Total Liabilities : €6,273 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Adient Total Liabilities?

Adient's Total Liabilities for the quarter that ended in Mar. 2024 was €6,273 Mil.

Adient's quarterly Total Liabilities declined from Sep. 2023 (€6,391.28 Mil) to Dec. 2023 (€6,074.21 Mil) but then increased from Dec. 2023 (€6,074.21 Mil) to Mar. 2024 (€6,272.56 Mil).

Adient's annual Total Liabilities increased from Sep. 2021 (€6,647.00 Mil) to Sep. 2022 (€6,805.38 Mil) but then declined from Sep. 2022 (€6,805.38 Mil) to Sep. 2023 (€6,391.28 Mil).

Adient Total Liabilities Historical Data

The historical data trend for Adient's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adient Total Liabilities Chart

Adient Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Total Liabilities

Get a 7-Day Free Trial

7,356.62

7,371.87

6,647.00

6,805.38

6,391.28

Adient Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															6,437.13	6,405.62	6,391.28	6,074.21	6,272.56

Adient Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Adient's Total Liabilities for the fiscal year that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3502.506	+	(2249.737	+	552.83
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	86.204)
	=	6,391

Total Liabilities	=	Total Assets (A: Sep. 2023 )	-	Total Equity (A: Sep. 2023 )
	=	8830.288	-	2439.011
	=	6,391

Adient's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3365.36	+	(2208.92	+	612.72
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	85.56)
	=	6,273

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	8535.76	-	2263.2
	=	6,273

Adient Total Liabilities Related Terms

Thank you for viewing the detailed overview of Adient's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Adient (FRA:18I) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Vehicles & Parts » Adient PLC (FRA:18I) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ADNT:USA

Address

3 Dublin Landings, North Wall Quay, IFSC, Dublin 1, Dublin, IRL, D01 H104

Website

https://www.adient.com

Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment into this new company. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated seating revenue from joint ventures after factoring in the sale was about $3.8 billion in fiscal 2023 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2023 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $15.4 billion.

Adient (FRA:18I) Headlines

No Headlines